Immune cell subsets in patients with bipolar disorder or schizophrenia with history of childhood maltreatment

Foiselle, Marianne; Lajnef, Mohamed; Hamdani, Nora; Boukouaci, Wahid; Wu, Ching-Lien; Naamoune, Soumia; Chami, Leïla; Mezoued, Esma; Richard, Jean-Romain; Bouassida, Jihène; Sugunasabesan, Sobika; Le Corvoisier, Philippe; Barrau, Caroline; Yolken, Robert; Leboyer, Marion; Tamouza, Ryad

doi:10.1016/j.bbi.2023.05.015

Cited by 13 publications

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a similar study by Foiselle et al (2023) , the authors measured naïve and memory CD4 + and CD8 + subpopulations in 152 mainly stabilized patients with BD, 118 patients with schizophrenia and 178 healthy controls. The objective of the study of Foiselle was to explore the role of childhood maltreatment and past infection exposure on these lymphocyte subpopulations in bipolar and psychotic disorders.…”

Section: Discussionmentioning

confidence: 99%

“…Although the objective in the study of Foiselle et al (2023) was an investigation into the role of childhood maltreatment and past infection, it was possible to make a direct comparison of the above-mentioned T cell subpopulations between patients with BD and healthy controls of the Foiselle study, since the authors provided group means and standard deviations. The differences in immune subpopulations between patients and controls together with the relevant demographic variables can be found in Supplementary Table S3 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Higher T central and lower effector memory cells in bipolar disorder: A differentiation abnormality?

Ioannou,

Simon,

Borkent

et al. 2024

Brain, Behavior, & Immunity - Health

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Higher T central and lower effector memory cells in bipolar disorder: A differentiation abnormality?

Ioannou,

Simon,

Borkent

et al. 2024

Brain, Behavior, & Immunity - Health

View full text Add to dashboard Cite

“…Schizophrenia and bipolar disorder are intricate pathologies influenced by various factors, including the social environment, lifestyle habits, age, and exposure to recurrent pathogens such as HCMV. For instance, a recent study has shown that schizophrenia and bipolar disorder patients who experienced childhood maltreatment exhibit elevated levels of HCMV antibodies and alterations in the frequencies of immune cell subsets compared to those who did not [ 28 ]. Furthermore, congenital HCMV has been shown to play a crucial role in the development of schizophrenia only when a specific allele is present in the fetus [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Spanish HCMV Seroprevalence in the 21st Century

Álvarez-Heredia,

Reina-Alfonso,

Domínguez-del-Castillo

et al. 2023

Viruses

View full text Add to dashboard Cite

Human cytomegalovirus (HCMV) is linked to age-related diseases like cardiovascular disease, neurodegenerative conditions, and cancer. It can also cause congenital defects and severe illness in immunocompromised individuals. Accurate HCMV seroprevalence assessment is essential for public health planning and identifying at-risk individuals. This is the first HCMV seroprevalence study conducted in the general Spanish adult population in 30 years. We studied HCMV seroprevalence and HCMV IgG antibody titres in healthy adult donors (HDs) and HCMV-related disease patients from 2010 to 2013 and 2020 to 2023, categorized by sex and age. We compared our data with 1993 and 1999 studies in Spain. The current HCMV seroprevalence among HDs in Spain is 73.48%. In women of childbearing age, HCMV seroprevalence has increased 1.4-fold in the last decade. HCMV-seropositive individuals comprise 89.83% of CVD patients, 69% of SMI patients, and 70.37% of COVID-19 patients. No differences in HCMV seroprevalence or HCMV IgG antibody titres were observed between patients and HDs. A significant reduction in Spanish HCMV seroprevalence among HDs was observed in 1993. However, women of childbearing age have shown an upturn in the last decade that may denote a health risk in newborns and a change in HCMV seroprevalence trends.

show abstract

“…In humans, adolescents at high risk for mood disorder have a reduced number of Tregs, negatively correlated with their inflammatory state (Snijders et al, 2016). Similarly, several studies have found a decrease in Tregs associated with pro-inflammatory phenotypes (Grosse et al, 2016) in adults with major depressive episodes, including in patients with bipolar depression (Bennabi et al, 2019;Foiselle et al, 2023;Tarantino et al, 2021). Recently, deficits in Tregs have been associated with the severity of depression in patients with MDD (Rachayon et al, 2024).…”

Section: Introductionmentioning

confidence: 99%

Low-dose interleukin-2 in patients with bipolar depression: a phase 2 randomised double-blind placebo-controlled trial

Leboyer,

Foiselle,

Tchitchek

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Immune abnormalities including an insufficiency of regulatory T cells (Treg) and increased blood-based inflammatory markers have been observed in bipolar disorders (BD), particularly during depression. As Tregs are pivotal to control inflammation, Treg stimulation by low-dose IL-2 (IL-2LD) could have a therapeutic impact on bipolar depression. We performed a randomized, double-blind, placebo-controlled (2 active: 1 placebo) proof-of-concept trial of add-on IL-2LDin patients with bipolar depression. Patients received a placebo or IL-2LD(1MIU) once a day for 5 days, and then once a week for 4 weeks starting on week 2. The primary objective was to demonstrate a biological Treg response to IL-2LDassessed by fold increase in Treg percentage of CD4+ cells from baseline to day 5. Secondary objectives included safety assessment and mood improvement throughout the study period. This trial is registered with ClinicalTrials.gov, numberNCT04133233. Fourteen patients with bipolar depression were included, with 4 receiving placebo and 10 IL-2LD. Baseline clinical and biological characteristics were balanced between groups. The primary evaluation criterion was met, with IL-2LDexpanding 1.17 [95% CI 1.01-1.34] vs 1.01 [95% CI 0.90 - 1.12] (p=0.0421) and activating Tregs. Secondary evaluation criteria were also met with significant improvements of depressive symptoms and global functioning from day-15 onwards in the IL-2LDtreated patients. The treatment was well-tolerated, with no serious adverse events related to treatment. This proof-of-concept trial shows that stimulating Tregs in patients with bipolar depression is safe and associated with clinical improvements. This supports a pathophysiological role of inflammation in BD and warrants pursuing the evaluation of IL-2LDas an adjunct treatment of major mood disorders.

show abstract

Immune cell subsets in patients with bipolar disorder or schizophrenia with history of childhood maltreatment

Cited by 13 publications

References 53 publications

Higher T central and lower effector memory cells in bipolar disorder: A differentiation abnormality?

Higher T central and lower effector memory cells in bipolar disorder: A differentiation abnormality?

Spanish HCMV Seroprevalence in the 21st Century

Low-dose interleukin-2 in patients with bipolar depression: a phase 2 randomised double-blind placebo-controlled trial

Contact Info

Product

Resources

About